- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Hilliard Lyons Reiterates Long Term Buy Rating On VIVO
Recent Articles by Craig Jones
- Pete Najarian Is Watching Medivation (MDVN)
- Fast Money Picks For February 9th (BIDU, DMND, LULU, LOW)
- Cramer Believes It Is Time To Buy Polo Ralph Lauren (RL)
- Benzinga's Top ETF Decliners (FAS, GDX, URE, TAN)
- Benzinga's Top ETF Gainers (DRV, FAZ, SKF, BDD)
Analyst Color
- Alberto-Culver Company’s (ACV) FY10 First-Quarter Review
- Cognizant Technology Solutions Corporation (CTSH) Reports Strong Results For The Forth-Quarter
- Consumer Technology Industry Update (ATVI, GME, SNE, ERTS)
- SAP Upgraded On Valuation
- ERTS Posts FQ3 Results Inline With Preannouncement
Analyst Ratings
Posted on 11/12/09 at 5:32pm by Craig Jones
Hilliard Lyons reiterated its "long term buy" rating on Meridian Bioscience Inc. (NASDAQ: VIVO). It estimates VIVO's 2010 EPS at $0.97 and if the company sustains its growth, Hilliard Lyons thinks that Meridian Bioscience's EPS will reach $1.10 in two or three years. Therefore, Hilliard Lyons has a price target of $27 per share.
Hilliard Lyons sees VIVO as reasonably priced company that has a strong financial position and an attractive dividend yield of about 3%.
VIVO's fourth fiscal quarter revenue increased 16% to $42.5M due to emergence of the swine flue. Meridian Bioscience Inc. (VIVO) dropped 1.53% today and closed at $22.50.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
There are 1 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Some pertinent points in
by Sam Reed on 01/08/10 12:44pm
Some pertinent points in there. I don’t agree with all you have said but the majority of it makes perfect sense...
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
